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Abstract
Background: Inflammation, both local and systemic, is a hallmark of chronic obstructive pulmonary disease
(COPD). Inflammatory mediators such as TNFa and GM-CSF are secreted by lung epithelium, alveolar macrophages
and other inflammatory cells and are thought to be important contributors in the pathogenesis of COPD. Indeed,
neutrophils are activated by these cytokines and these cells are one of the major inflammatory cell types recruited
to the pulmonary compartment of COPD patients. Furthermore, these inflammatory mediators are found in the
peripheral blood of COPD patients and, therefore, we hypothesized that TNFa/GM-CSF-induced protein profiles can
be found in peripheral neutrophils of COPD patients.
Methods: Using fluorescence 2-dimensional difference gel electrophoresis we investigated differentially regulated
proteins in peripheral neutrophils from COPD patients and healthy age-matched control subjects. Furthermore,
protein profiles from COPD patients were compared with those of neutrophils of healthy age-matched controls
that were stimulated with TNFa and/or GM-CSF in vitro. Protein gels were compared using DeCyder 7.0 software.
Results: We identified 7 significantly regulated protein spots between peripheral neutrophils from COPD patients
and age-matched healthy control subjects. Stimulation of peripheral neutrophils with TNFa, GM-CSF or TNFa +
GM-CSF in vitro resulted in 13, 20 and 22 regulated protein spots, respectively. However, these cytokine-induced
protein differences did not correspond with the protein differences found in neutrophils from COPD patients.
Conclusion: These results show that neutrophils from COPD patients have a unique protein profile compared to
neutrophils from healthy age-matched controls. Furthermore, the neutrophil profiles of COPD patients do not reflect
putative dominant signals induced by TNFa, GM-CSF or their combination. Our results indicate that systemic neutrophil
responses in COPD patients are caused by a unique but subtle interplay between multiple inflammatory signals.
Background
COPD is classified by the guidelines of the Global Initia-
tive for Chronic Obstructive Lung Disease, which is
based on lung function parameters: forced expiratory
volume in 1 second (FEV1) and forced vital capacity
(FVC) [1]. However, it has become increasingly clear that
the GOLD classification does not represent the complex
local and systemic inflammation in COPD [2-4]. Part of
this inflammatory process is the secretion of inflamma-
tory mediators by lung epithelium, alveolar macrophages
and other inflammatory cells [5]. These inflammatory
mediators affect the local tissue and attract inflammatory
cells to the site of inflammation. For instance, alveolar
macrophages secrete tumor necrosis factor-a (TNFa)[ 6 ]
and granulocyte macrophage-colony stimulating factor
(GM-CSF) [7] upon stimulation with cigarette smoke and
increased levels of these cytokines are measured in the
bronchiolar alveolar lavage (BAL) fluid, sputum or per-
ipheral blood of COPD patients [8-12]. A central role for
GM-CSF in smoke-induced inflammation was shown by
intranasal administration of anti-GM-CSF antibodies to
mice exposed to cigarette smoke, which reduced BAL
fluid macrophages, neutrophils and TNFa synthesis [13].
Increased levels of TNFa were found in exhaled breath
condensates [14], sputum [15] and serum of COPD
patients [16-18].
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COPD patients [11,16-20]. However, these differences are
often small compared to healthy controls, and the biologi-
cal activity of these cytokines is dependent on the ratio
with their naturally occurring inhibitors and other cyto-
kines. Therefore, the use of peripheral neutrophils that
have integrated all pro- and anti-inflammatory signals
in vivo might be a more biologically relevant read-out to
measure the systemic inflammatory status of a COPD
patient. Previous studies in our laboratory showed that
stimulation of neutrophils with either TNFa or GM-CSF
in vitro resulted in differential expression of genes encod-
ing chemokines and cytokines [21]. Various genes were
similarly induced upon stimulation with TNFa or GM-
CSF. More interestingly, the combination of these cyto-
kines induced a unique mRNA pattern, which was distinct
from the profiles induced by either cytokine alone. For
instance, GM-CSF did not affect the expression of CD83
mRNA in control cells, but inhibited its expression
induced by TNFa. This GM-CSF-induced inhibition was
dose-dependent and was confirmed at the protein level by
Western blot analysis [22]. These results show that inte-
gration of multiple cytokine signals can result in a distinct
phenotype of the neutrophils.
Our study was designed to define the protein profiles of
neutrophils found in COPD patients and to compare these
with protein profiles found after in vitro stimulation. We
performed fluorescence 2-dimensional (2D) difference gel
electrophoresis (DIGE) on peripheral neutrophils from
COPD patients and age-matched healthy controls and
compared the differentially regulated proteins with differ-
entially regulated proteins induced by TNFa and/or GM-
CSF in vitro. We report 7 protein differences in neutrophils
from COPD patients compared to neutrophils from
healthy age-matched control subjects. TNFa, GM-CSF or
TNFa + GM-CSF stimulation in vitro resulted in 13,
20 and 22 protein differences, respectively. Although cyto-
kine stimulation of peripheral neutrophils in vitro showed
differential protein expression, this did not correspond to
differential protein expression found in neutrophils from
COPD patients. Therefore, the peripheral neutrophil pro-
teins regulated in COPD patients did not resemble TNFa-
or GM-CSF-induced protein profiles. However, differential
p r o t e i ne x p r e s s i o ni nn e u t r ophils from COPD patients
compared to age-matched healthy controls shows that
using this technique a disease related neutrophil profile
could be found.
Methods
Reagents
Ficoll-Paque was obtained from GE Healthcare (Uppsala,
Sweden). Human serum albumin (HSA) was from Sanquin
(Amsterdam, the Netherlands). Recombinant human
TNFa was purchased from Roche (Indianapolis, IN).
Recombinant human GM-CSF was a gift from Prof.
A. Lopez (Institute of Medical and Veterinary Sciences,
Adelaide, Australia). All other materials were reagent
grade.
Patients and healthy control subjects
We included 13 patients with a diagnosis of COPD accord-
ing to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) [1] and 6 healthy age-matched control
subjects (see for demographics table 1). All patients had
stable COPD without an exacerbation in the last four
weeks before entering the study. Patients with other inflam-
matory conditions, heart failure and treatment with oral
glucocorticosteroids were excluded. Dyspnea was rated
with the Medical Research Council (MRC) scores [23]. The
medical ethics committee of the University Medical Center
Utrecht (Utrecht, The Netherlands) approved the study,
and all subjects provided written informed consent.
Granulocyte isolation
Granulocytes were isolated from whole blood anticoa-
gulated with sodium-heparin from COPD patients or
Table 1 Characteristics of study subjects
Control COPD
Characteristics (n = 6) (n = 13) Statistics
Age. Yr 60.3 (3.5) 65.5 (2.5) n.s.
Gender
Male 5 11
Female 1 2
FEV1
L 3.33 (0.44) 1.40 (0.16) 0,006
% predicted 104.5 (8.4) 46.8 (4.9) < 0.001
FEV1/FVC ratio 78.0 (2.0) 45.4 (4.4) < 0.001
GOLD
II 5
III 6
IV 2
MRC score
06
14
24
35
Smoking status
Current smokers 2
Ex-smokers 3 11
Never smokers 3
Weight. kg 74.7 (3.6) 81.7 (3.8) n.s.
Height. cm 175 (4) 178 (3) n.s.
BMI. kg/m
2 24.4 (0.8) 25.8 (0.9) n.s.
hsCRP, mg/L 3.8 (2.4) 4.6 (1.8) n.s.
Leukocyte cell count. x10
6 cells/mL 6.7 (0.8) 8.1 (0.5) n.s.
Data is represented as mean ± standard error of the mean
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diluted 2.5:1 with PBS containing trisodium citrate
(0.4% w/v, pH 7.4) and human pasteurized plasma-
protein solution (4 g/L). Mononuclear cells and granulo-
cytes were separated by centrifugation using Ficoll-Paque.
Erythrocytes were lysed in isotonic ice-cold NH4Cl solu-
tion (8.3 g/L NH4Cl, 1 g/L KHCO3 and 37 mg/L EDTA)
followed by centrifugation at 4°C. After isolation, granulo-
cytes were washed in PBS containing trisodium citrate
(0.4% w/v, pH 7.4) and human pasteurized plasma-protein
solution (4 g/L) and resuspended in HEPES buffered
RPMI 1640 supplemented with 0.5% (w/v) HSA. Purity
o fn e u t r o p h i l sw a s> 9 5 %w i t he o s i n o p h i l sa sm a j o r
contaminant.
Neutrophil stimulation and protein extracts preparation
Neutrophils (5 × 10
6/mL) in HEPES buffered RPMI 1640
supplemented with 0.5% (w/v) HSA were incubated for
30 min at 37°C. Subsequently, neutrophils of COPD
patients and healthy age-matched controls were immedi-
ately prepared for protein extracts (see below). Further-
more, neutrophils of healthy age-matched controls were
incubated without cytokines or stimulated with TNFa
(100 U/mL), GM-CSF (100 pM) or both for 4 hours at
37°C. All neutrophil samples (1.10
7/sample) were washed
twice (0.34 M sucrose, 1 mM EDTA, 10 mM Tris) and
lysed in lysis buffer (10 mM Tris pH 7.4, 10% glycerol, 1%
NP40, 50 mM NaF, 20 mM tetra-Na pyrophosphate,
1m MD T T ,2m Mv a n a d a t e ,1m MP M S F ,2m MD F P
and 1 × Complete EDTA-free protease inhibitor cocktail
tablet (Roche)). Proteins were precipitated with 80% acet-
one and dissolved in labeling buffer (8 M Urea, 2 M
Thiourea, 4% CHAPS, 10 mM Tris pH 8.5).
CyDye labeling
The DIGE technology is based on differential protein
labeling with different fluorescent CyDyes, which allows
sample multiplexing. This method is an unbiased
approach to identify differences in protein expression and
the use of an internal standard enables identification of
protein differences as small as 10% [24]. Protein extracts
were labeled using the fluorescent cyanine dyes developed
for 2D-DIGE technology (GE Healthcare) following manu-
facturer’s protocol with some minor modifications. Protein
extracts (30 μg) were labeled with 300 pmol of fluorescent
dye (Cy2, Cy3, or Cy5). Protein samples from COPD
patients, healthy control or in-vitro stimulated neutrophils
were randomly labeled with Cy3 or Cy5. And each dye
was used a similar number of times in each group to
exclude effects of preferential labeling. An internal stan-
dard, created by pooling 15 μg of each protein sample, was
labeled with Cy2. Labeling was stopped by adding lysine
and equal volume of 2 × IEF buffer (8 M Urea, 2 M
Thiourea, 4% CHAPS, 300 mM DTT, 1.0% IPG buffer 3-
10NL, 0.004% Broomphenolblue) to each sample.
2D-gel electrophoresis and analysis
Two protein samples (Cy3 and Cy5) were mixed with the
Cy2-labeled internal control. Protein samples were pas-
sively rehydrated into 24 cm pH 3-10 NL strips (GE
Healthcare, Uppsala, Sweden) for 10 hours followed by
isoelectric focusing using a manifold-equipped IPGphor
IEF unit (GE Healthcare) according to the manufacturer’s
protocol. The cysteine sulfhydryls were reduced with 1.0%
DTT and carbamidomethylated with 2.5% Iodoacetamide
in equilibration buffer (30% glycerol, 2% SDS, 6 M urea,
75 mM Tris, pH 8.8). Second dimensional SDS-PAGE was
performed on hand-cast 12% SDS-PAGE gels using low
fluorescence glass plates. Electrophoresis was carried out
at 0.2 watts/gel for 2 hours followed by 1 watts/gel until
completion using an Ettan DALT-12 unit (GE Healthcare).
Gels were scanned using a Typhoon 9410 imager at
100 μm resolution (GE Healthcare). Scan settings were
optimized for a maximal signal of 85.000 counts. Gel
images were cropped using ImageQuantTL 2003 (GE
Healthcare), spot detection was performed with DeCyder
7.0 DIA (Difference In-gel Analysis) software (GE Health-
care) and gel images were matched using DeCyder 7.0
BVA (Biological Variation Analysis) software (GE Health-
care). Statistical analysis was performed using 1-ANOVA
DeCyder 7.0 BVA. For 2D-gel analysis p < 0.01 was con-
sidered statistically significant.
Statistical analysis
Statistical analysis of 2D-DIGE spot intensity was per-
formed using DeCyder 7.0 BVA or EDA software (GE
Healthcare, Uppsala, Sweden). Statistical analysis of
patient characteristics was performed using an indepen-
dent sample t tests with statistical software package SPSS
16.0.
Results
Neutrophils from COPD patients show differentially
regulated proteins compared to healthy controls
We first tested the hypothesis whether systemic inflam-
mation in COPD would be reflected by differences in
protein expression compared to neutrophil protein
expression from healthy control subjects. Therefore, we
analyzed the neutrophil proteome from COPD patients
and healthy age-matched control subjects by 2D-DIGE.
We compared peripheral neutrophil protein expression
of 6 healthy age-matched control subjects with those of
13 COPD patients (for demographics see table 1). No sig-
nificant differences were present in age, weight, length,
BMI or leukocyte count, whereas FEV1,a n dF E V 1/FVC
ratio were significantly different between the two groups.
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systemic inflammation but no significant differences
were found.
Next, we tested whether neutrophils from COPD
patients showed significant protein differences compared
to healthy controls. Neutrophil protein lysates of freshly
isolated neutrophils from healthy controls or COPD
patients were prepared, labeled with Cy3 or Cy5 and
combined with an internal reference control stained
with Cy2. Protein samples were separated by 2D-DIGE
and analysis with DeCyder 7.0 identified 1200 - 2200
protein spots by a volume filter exclusion of 30.000 in
the differential in-gel analysis (DIA) software. The indi-
vidual spotmaps were matched in the biological varia-
tion analysis (BVA) software and statistical analysis
between healthy controls and COPD patients showed 7
protein spots that were at least 1.10-fold differentially
regulated with a p < 0.01 (Figure 1 and Table 2). The
peripheral neutrophil spotmaps from COPD patients
could be separated in a principal component analysis
(PCA) from peripheral neutrophil spotmaps based on
the differentially regulated proteins from healthy con-
trols, showing that the differentially regulated proteins
have a discriminatory power (Figure 2).
TNFa- and GM-CSF-modulated protein expression of
human neutrophils
The differentially regulated proteins identified in neutro-
phils from COPD patients might have been induced
upon exposure to dominant inflammatory mediators in
t h ep e r i p h e r a lb l o o d .W es e to u tas t u d yi nw h i c hw e
compared the profile of neutrophils from COPD patients
with in vitro cytokine-stimulated neutrophils to identify
proteins that are similarly regulated and predict which
218 
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1012 
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1695 
3  10 
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Figure 1 2D-DIGE of peripheral neutrophils from COPD patients and healthy controls. Neutrophils were isolated from the peripheral blood and
protein lysates for 2D-DIGE were prepared. Proteins were focused on 24 cm pH 3-10 NL IEF strips and separated by 12% SDS-PAGE. Representative
image of the biological variation analysis (BVA) software is shown. The differentially regulated proteins are indicated by the red spot boundaries.
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inflammation. We tested TNFa and GM-CSF because of
their well-documented association with COPD
[8,11,12,14-18]. Neutrophils from age-matched healthy
controls were either left untreated or stimulated with
TNFa (100 U/mL), GM-CSF (100 pM) or the combina-
tion for 4 hours at 37°C and, thereafter, protein lysates
were made (n = 5). Subsequently, samples were labeled
with Cy3 or Cy5 and were combined with an internal
reference control stained with Cy2 and analyzed by 2D-
DIGE. BVA analysis was performed as described above.
Statistical analysis showed 13 protein spots to be differ-
entially regulated more than 1.10-fold (1-ANOVA p <
0.01) following TNFa stimulation and 20 protein spots
following GM-CSF stimulation, which included the 13
TNFa regulated protein spots (Table 2). Although TNFa
did not show cytokine-specific regulated protein spots, it
showed a potentiating effect on multiple GM-CSF-
induced protein spots. The combination of TNFa and
GM-CSF showed 22 differentially regulated protein
spots. Two spots were specifically regulated more than
1.10-fold by the combination of TNFa + GM-CSF.
Differentially regulated proteins in neutrophils from
COPD patients do not correspond to differentially
regulated protein spots in cytokine-stimulated
neutrophils in vitro
GM-CSF and TNFa both induced expression of proteins
in neutrophils in vitro and we tested the hypothesis
Table 2 Analysis of differentially regulated protein spots in neutrophils from COPD patients and in-vitro stimulated
neutrophils
No. regulated spots
Control vs. COPD 7
Not stimulated vs. TNFa 13
Not stimulated vs. GM-CSF 20
Not stimulated vs. TNFa + GM-CSF 22
No. regulated spots in COPD No. regulated spots by GM-CSF
Control vs. COPD 7 0
Not stimulated vs. GM-CSF 0 20
COPD 
Control 
Figure 2 COPD spotmaps were discriminative in a principal
component analysis. Data of the significant differential regulated
proteins identified in the BVA of peripheral neutrophils from COPD
patients (Spot ID 218, 318, 479, 674, 1012, 1332 and 1695) were
imported into the extended data analysis (EDA) software. Principal
component analysis (PCA) was performed on 6 healthy control
(light blue) and 13 COPD (orange) spotmaps.
COPD 
Control 
TNFα 
TNFα + GM-CSF 
GM-CSF 
Not stimulated 
Figure 3 COPD spotmaps did not show a GM-CSF or TNFa-
induced protein profile in a principal component analysis. Data
of spot ID 218, 318, 479, 674, 1012, 1332 and 1695 (differentially
regulated in COPD patients) from the COPD patient and in vitro
stimulation BVA were imported into the EDA software. Principal
component analysis (PCA) was performed on 5 non-stimulated (NS)
(green), 5 TNFa-stimulated (red), 5 GM-CSF-stimulated (blue), 5
TNFa+GM-CSF-stimulated neutrophil spotmaps (purple), 6 healthy
controls (light blue) and 13 COPD neutrophil spotmaps (orange).
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regulated proteins in neutrophils from COPD patients.
Seven proteins (Figure 1; Spot ID 218, 318, 479, 674,
1012, 1332 and 1695) were significantly different
between neutrophils of healthy age-matched controls
compared to neutrophils from COPD patients. These
seven protein spots were traced back in the 2D-DIGE
gels of in vitro stimulated neutrophils. Not any of these
7 protein spots showed differential regulation by GM-
CSF (Table 2) or TNFa ( d a t an o ts h o w n ) .V i c ev e r s a ,
t h e2 0p r o t e i ns p o t st h a tw e r ed i f f e r e n tb e t w e e nu n s t i -
mulated neutrophils and GM-CSF stimulated neutro-
phils in vitro were not differentially regulated between
neutrophils of healthy controls and COPD patients
(Table 2). As a consequence, the COPD spotmaps
(orange) did not cluster with TNFa-stimulated neutro-
phils (red) or GM-CSF-stimulated neutrophils (blue) in
the PCA, based on the differentially regulated proteins
in COPD patients (Figure 3). Therefore, this analysis
s h o w st h a tt h ep r o t e i np r o f i l e so fC O P Dp a t i e n t sa r e
not reflected by GM-CSF and/or TNFa-stimulated per-
ipheral neutrophil profiles.
Discussion
Increased neutrophil numbers and multiple inflammatory
mediators have been found in sputum, bronchoalveolar
lavage (BAL) fluid, bronchial biopsies and peripheral
blood of COPD patients [8-12,25-27]. Therefore, we set
out experiments to measure the neutrophil protein
expression ex vivo as a means to identify cytokines that
are dominant in the systemic inflammation in COPD
patients. We have used 2D-DIGE, a novel technique that
uses an internal reference sample in all 2D-gels, which
enables the identification of p r o t e i ne x p r e s s i o nd i f f e r -
ences as small as 10% [24]. Although the control group
only includes 6 subjects, in-vitro stimulation of these
neutrophils showed reproducible differences in protein
expression. Furthermore, various 2D-DIGE publications
have used similar group sizes [28-30]. Therefore, this
technique is suitable to detect p r o t e i ne x p r e s s i o nd i f f e r -
ences in relatively small study groups.
We performed for the first time 2D-DIGE on peripheral
neutrophils from stable COPD patients and age-matched
healthy control subjects and identified 7 significant (1-
ANOVA p < 0.01) protein differences. A limitation of the
study is the lack of an age-matched control group that
smokes but do not have signs of COPD. The possible con-
founder in our study is that the differences found between
healthy controls and COPD patients are smoking related
and not disease related. Therefore, in additional PCA com-
parisons we excluded spotmaps from current smokers
from the COPD group, which did not affect the clustering
(data not shown). Also, comparing spotmaps from COPD
patients with control spotmaps of either ex-smokers or
non-smokers in the PCA showed clustering of COPD
spotmaps apart from control spotmaps (data not shown).
Based on these observations we find it unlikely that smok-
ing is the reason for the differential neutrophil protein
expression found in the COPD patients. Therefore, we
hypothesize that the protein differences represent a base-
line systemic inflammation in COPD patients. The protein
differences found in neutrophils from COPD patients
were subsequently compared with in vitro cytokine-stimu-
lated neutrophils. For this approach, we selected in vitro
stimulation with TNFa and/or GM-CSF because these
cytokines are extensively described to be involved in the
inflammation and pathogenesis of COPD. TNFa is an
interesting cytokine in regard to systemic inflammation
because it is linked to extrapulmonary manifestations of
COPD such as osteopenia [31] and muscle wasting [32].
An important pathway induced by TNFa is the NF-B
pathway, and increased NF-B activity has been shown in
sputum neutrophils [33] and macrophages [34] of COPD
patients. Also, GM-CSF is an important cytokine in the
pathogenesis of COPD. Recently, Vlahos et. al. showed
that mice exposed to cigarette smoke that were treated
with neutralizing antibodiesa g a i n s tG M - C S Fe x h i b i t e d
reduced BAL fluid macrophages and neutrophils [13].
Also, TNFa, MIP-2 and MMP-12 mRNA levels were
reduced in the lungs of anti-GM-CSF treated mice. This
shows that GM-CSF is a key mediator in smoke-induced
airway inflammation. We have previously shown that in
vitro stimulation of neutrophils with either TNFa or GM-
CSF resulted in differential expression of genes encoding
for chemokines and cytokines [21]. In our current proteo-
mics approach in vitro stimulation of peripheral neutro-
phils with TNFa or GM-CSF resulted in differential
protein expression of 13 and 20 protein spots, respectively.
All proteins regulated by TNFa were also regulated by
GM-CSF, showing that both cytokines show redundancy
in regulating protein expression. It is surprising that
TNFa did not show cytokine-specific regulation of protein
spots because it is an important stimulator for the NF-B
pathway, regulating multiple inflammatory mediators that
are not regulated by GM-CSF [21]. Indeed, we previously
showed that TNF-a increased the expression of chemo-
kines in neutrophils on mRNA level in vitro [21]. Also, we
have confirmed TNF-a-induced production of IL-1b on
protein level in neutrophils in vitro [35]. A possible expla-
nation could be that the expression levels of these inflam-
matory mediators in the neutrophils are too low to be
detected by 2D-DIGE.
GM-CSF-induced protein expression in neutrophils in
vitro was compared with protein expression of neutrophils
from COPD patients. Protein differences that were found
in neutrophils from COPD patients did not correspond to
protein differences found in GM-CSF-stimulated neutro-
phils (Figure 3, Table 2). It is very well possible that other
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tein expression in peripheral neutrophils from COPD
patients. For instance, increased levels of IL-6, IL-8, and
CRP were found in the peripheral blood op COPD
patients [36,37]. Which of these factors, or combination of
factors, play a role in the regulation of neutrophil proteins
in COPD patients is currently not known. At least, we can
exclude a prominent role for TNFa or GM-CSF on per-
ipheral blood neutrophils. The identification of the differ-
entially regulated neutrophil protein spots from COPD
patients by mass spectrometry might delineate the inflam-
matory factors involved in neutrophil protein regulation
in vivo, however, this was not the aim of this investigation.
Our data do not support the hypothesis that TNFa and
GM-CSF drive systemic inflammation in stable COPD
patients with a normal BMI (Table 1). Interestingly, we
did not find increased hsCRP levels in our cohort of
COPD patients, which is a marker for systemic inflamma-
tion. The most likely explanation for the low C-reactive
protein (CRP) levels is the strict inclusion of stable COPD
patients. Indeed, increased levels of acute phase proteins
such as fibrinogen or CRP in COPD patients are mainly
found during exacerbations [37-42]. Apparently, the differ-
ences found in the neutrophil proteome are not caused by
an acute phase systemic inflammation since CRP levels
were not significantly different between our included
COPD patients and age-matched healthy control subjects.
Conclusion
Systemic inflammation in COPD was determined by the
analysis of the proteomes of peripheral blood neutrophils.
The proteomes of the peripheral neutrophils of the COPD
patients were not similar to peripheral neutrophils stimu-
lated by TNFa and/or GM-CSF, neither did they correlate
with increases in CRP. This indicates that systemic inflam-
mation in COPD as visualized by peripheral neutrophil
protein profiles is caused by a unique but subtle interplay
between multiple inflammatory signals.
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